NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

The Department of Health and Human Services (HHS), Office of Minority Health requests that the National Academies of Sciences, Engineering, and Medicine convene an ad hoc committee to develop a ...

Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in sub-Saharan Africa. Every year, hundreds of thousands of infants are born with ...

LMP Capital and Income Fund offers an 8% dividend yield, focusing on income through diverse investments in MLPs, REITs, and common stocks. SCD's strategy includes a mix of energy and tech stocks, ...

Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026. In a presentation set ...

The global withdrawal of voxelotor (Oxbryta, Pfizer) has left clinicians who treat sickle cell disease (SCD) with the urgent task of reaching patients taking the medicine, while trying to understand ...

Sixteen patients dosed with Pfizer’s sickle cell disease drug Oxbryta® (voxelotor) in a pair of clinical trials have died, European regulators disclosed hours before Pfizer said it was voluntarily ...

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.